Chasing Bristol Myers and Pfizer, Connect fails phase 2 ulcerative colitis trial but spies path forwardnews2022-05-04T11:54:41+00:00May 4th, 2022|FierceBiotech|
BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnershipsnews2022-05-03T22:38:33+00:00May 3rd, 2022|FierceBiotech|
Record-breaking 2021 revenue shows there’s more to Swiss biotech sector than Roche, Novartisnews2022-05-03T18:22:12+00:00May 3rd, 2022|FierceBiotech|
Another Pfizer gene therapy is free of FDA hold, but delay continuesnews2022-05-03T15:00:54+00:00May 3rd, 2022|FierceBiotech|
Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drugnews2022-05-03T14:40:12+00:00May 3rd, 2022|FierceBiotech|
After a dismal last year, Sesen Bio grasps for alternatives to stay afloatnews2022-05-03T14:18:01+00:00May 3rd, 2022|FierceBiotech|
Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to benews2022-05-03T14:04:56+00:00May 3rd, 2022|FierceBiotech|
Early clinical data on psilocybin in anorexia point Compass to potential new opportunitynews2022-05-03T12:34:54+00:00May 3rd, 2022|FierceBiotech|
Dianthus to follow ‘north star’ on mission to reduce autoimmune injections with $100M fundingnews2022-05-03T12:19:22+00:00May 3rd, 2022|FierceBiotech|
Tackling toxicity, Tubulis lands $63M to advance ADC pipeline spearheaded by Adcetris rivalnews2022-05-03T07:10:53+00:00May 3rd, 2022|FierceBiotech|
